EP300 and Alzheimer disease: By targeting the CBP/p300 signaling pathway with small molecule HADC inhibitors, one study showed that neuronal survival could be enhanced and the progressive neurodegeneration slowed or prevented and memory impairments could be reversed, which is associated with the early-stage of AD [11].